Incidence and prevalence of lymphatic neoplasms in Poland 2009–2015 determined on analysis of National Health Fund data used in the ‘Maps of healthcare needs — database of systemic and implementation analyses’ project

Introduction: The need for epidemiological data on blood neoplasms is driven by both systemic and scientific requirements. Due to the fact that all services provided to patients with these cancers in Poland are reported to the National Health Fund (NHF), the aim of this study was to try to use this data to estimate the incidence and prevalence of lymphatic neoplasms in Poland, as well as to determine overall survival (OS) in this group of patients. Materials and methods: The analysis was carried out as part of the ‘Maps of health needs — database of system and implementation analyses’ project, co-financed by the European Union through the European Social Fund under the Operational Program Knowledge Education Development. Results : The registered incidence of follicular lymphoma (FL) in 2014 was 1.74/100,000, whilst the registered prevalence was 15.56/100,000. The median OS of patients registered in the NHF system in 2009–2015 with an FL diagnosis was over 60 months, and the estimated 3- and 5-year OS rates were 76.6% and 68.8% respectively. In 2014, the incidence and prevalence of diffuse large B-cell lymphomas (DLBCL) was 3.76/100,000 and 27.48/100,000, respectively. The median OS was over 60 months, and the estimated 3- and 5-year OS rates were 68.7% and 61.1%, respectively. On the other hand, the incidence and prevalence of chronic lymphocytic leukemia (CLL) were 8.65/100,000/year and 38.28/100,000/year, respectively. The median OS was over 60 months, and the estimated 3- and 5-year OS rates were 77.8% and 64.8%, respectively. In the case of plasma cell myeloma (PCM), the registered incidence and prevalence were 4.92/100,000/year and 23.28/100,000/year, respectively. The median OS was 60 months, and the 3- and 5-year OS rates were 62.8% and 49.7%, respectively. Conclusions: The data reported to the National Health Fund in order to obtain reimbursement of medical services seems to be the most reliable data covering such a large population of patients. The results are similar to data from European and American registries for DLBCL and PCM. However, the FL and CLL data requires further verification.